» Authors » Cristina Al-Khalili Szigyarto

Cristina Al-Khalili Szigyarto

Explore the profile of Cristina Al-Khalili Szigyarto including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 11276
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Johansson C, Hunt H, Signorelli M, Edfors F, Hober A, Svensson A, et al.
Clin Proteomics . 2023 Jun; 20(1):23. PMID: 37308827
Background: Molecular components in blood, such as proteins, are used as biomarkers to detect or predict disease states, guide clinical interventions and aid in the development of therapies. While multiplexing...
2.
Rossi R, Johansson C, Heywood W, Vinette H, Jensen G, Tegel H, et al.
Int J Mol Sci . 2023 Mar; 24(6). PMID: 36982290
Duchenne muscular dystrophy (DMD) is a rare neuromuscular disease caused by pathogenic variations in the gene. There is a need for robust DMD biomarkers for diagnostic screening and to aid...
3.
Signorelli M, Spitali P, Szigyarto C, Tsonaka R
Stat Med . 2021 Aug; 40(27):6178-6196. PMID: 34464990
Longitudinal and high-dimensional measurements have become increasingly common in biomedical research. However, methods to predict survival outcomes using covariates that are both longitudinal and high-dimensional are currently missing. In this...
4.
Rossi R, Falzarano M, Osman H, Armaroli A, Scotton C, Mantuano P, et al.
Front Physiol . 2021 Jul; 12:678974. PMID: 34305639
Duchenne muscular dystrophy (DMD) is a rare genetic disease due to dystrophin gene mutations which cause progressive weakness and muscle wasting. Circadian rhythm coordinates biological processes with the 24-h cycle...
5.
Szigyarto C
Expert Rev Proteomics . 2020 Jul; 17(5):365-375. PMID: 32713262
Introduction: Early biomarker discovery studies have praised the value of their emerging results, predicting an unprecedented impact on health care. Biomarkers are expected to provide tests with increased specificity and...
6.
Previtali S, Gidaro T, Diaz-Manera J, Zambon A, Carnesecchi S, Roux-Lombard P, et al.
Pharmacol Res . 2020 Jun; 159:104999. PMID: 32535224
Rimeporide, a first-in-class sodium/proton exchanger Type 1 inhibitor (NHE-1 inhibitor) is repositioned by EspeRare for patients with Duchenne Muscular Dystrophy (DMD). Historically, NHE-1 inhibitors were developed for cardiac therapeutic interventions....
7.
Strandberg K, Ayoglu B, Roos A, Reza M, Niks E, Signorelli M, et al.
J Neuromuscul Dis . 2020 May; 7(3):231-246. PMID: 32390640
Background: Duchenne Muscular Dystrophy is a severe, incurable disorder caused by mutations in the dystrophin gene. The disease is characterized by decreased muscle function, impaired muscle regeneration and increased inflammation....
8.
Kennedy S, Jarboui M, Srihari S, Raso C, Bryan K, Dernayka L, et al.
Nat Commun . 2020 Jan; 11(1):499. PMID: 31980649
Protein-protein-interaction networks (PPINs) organize fundamental biological processes, but how oncogenic mutations impact these interactions and their functions at a network-level scale is poorly understood. Here, we analyze how a common...
9.
Signorelli M, Ayoglu B, Johansson C, Lochmuller H, Straub V, Muntoni F, et al.
J Cachexia Sarcopenia Muscle . 2019 Dec; 11(2):505-517. PMID: 31881125
Background: Duchenne muscular dystrophy (DMD) is a fatal disease for which no cure is available. Clinical trials have shown to be largely underpowered due to inter-individual variability and noisy outcome...
10.
Fasterius E, Uhlen M, Szigyarto C
Sci Rep . 2019 Jul; 9(1):9524. PMID: 31267007
Inter- and intra-tumour heterogeneity is caused by genetic and non-genetic factors, leading to severe clinical implications. High-throughput sequencing technologies provide unprecedented tools to analyse DNA and RNA in single cells...